Taiwan In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort to transform the island into a premier global hub for Cell and Gene Therapy (C>) manufacturing and development. This state-driven…
Taiwan With US-China geopolitical tensions pushing multinational pharma to seek manufacturing bases outside China, does Taiwan’s CDMO sector offer a compelling alternative? Recent US policy moves could reshape the global pharmaceutical supply chain. Most significantly, by blocking any company that receives federal funding or government contracts from using ‘high-risk’ Chinese…
Taiwan Sean Chang, CEO of Locus Cell, explains how his clinical CAR-T background led him to build a Taiwan-based CDMO for advanced cell therapies. The company is scaling Southeast Asia’s largest GMP facility, leveraging Taiwan’s manufacturing discipline, regulatory reforms and global partnerships to deliver high-quality, cost-competitive production bridging academic innovation and…
See our Cookie Privacy Policy Here
